Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01485874 · ClinicalTrials.gov registry record · Phase 1
Doxorubicin + BIBF 1120 in Patients for Ovarian Cancer
A Phase 1 study, sponsored by Hoosier Cancer Research Network.
- Terminated
- Registry status
- Phase 1
- Development phase
- 11
- Enrollment target
NCT01485874: Clinical Trial Phase 1 study, sponsored by Hoosier Cancer Research Network.
NCT01485874 is a Phase 1 study that was terminated before completion, run by Hoosier Cancer Research Network. The registered enrollment target is 11 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (82% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01485874, a Phase 1 study, was terminated before completion, sponsored by Hoosier Cancer Research Network.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 11 participants
- Enrollment target
Study Summary
The purpose of this trial is to determine whether BIBF 1120 can be safely combined with pegylated liposomal doxorubicin (phase I), and to determine the clinical activity of the combination in patients with platinum-resistant ovarian cancer (phase II).
Primary Outcome
To find the maximum tolerated dose (MTD) to be used during the Phase II trial and evaluate the safety and toxicity of the combination BIBF 1120 plus PLD in patients with recurrent or resistant epithelial ovarian or endometrial cancer.
Interventions
- DRUG BIBF 1120
- DRUG Doxil (Pegylated Liposomal Doxorubicin)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 11 participants |
| Start Date | 2011-11 |
| Est. Completion | 2015-12 |
| Phase | Phase 1 |
Why NCT01485874 stopped before completion
NCT01485874 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 11 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (82% lower).
The record links to 0 conditions, and to 2 interventions - of which BIBF 1120 is the first listed.
NCT01485874 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01485874 about?
NCT01485874 is a clinical study titled "Doxorubicin + BIBF 1120 in Patients for Ovarian Cancer". The purpose of this trial is to determine whether BIBF 1120 can be safely combined with pegylated liposomal doxorubicin (phase I), and to determine the clinical activity of the combination in patients with platinum-resistant ovarian cancer (phase II).
What is the current status of trial NCT01485874?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 11 participants. The study started on 2011-11. Estimated completion is 2015-12.
What interventions are being tested in trial NCT01485874?
The interventions under investigation include: BIBF 1120 (DRUG), Doxil (Pegylated Liposomal Doxorubicin) (DRUG).
Who is sponsoring clinical trial NCT01485874?
This trial is sponsored by Hoosier Cancer Research Network, which has 26 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01485874's enrollment target sits among peer trials
11 1911th of 2000 higher than 88 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03114462 · 11 participants · Phase 1
Trial of Stereotactic HYpofractionateD RadioAblative (HYDRA) Treatment of Laryngeal Cancer
- NCT06039709 · 11 participants · Phase 1
Sonodynamic Therapy in Patients With Recurrent GBM
- NCT06425380 · 11 participants · NA
Pilot Open-Label Trial of Resistant Potato Starch in Patients With Cirrhosis and Overt Hepatic Encephalopathy
- NCT06472661 · 11 participants · Early Phase 1
FUSA With Intratumoral PolyICLC in Regionally Advanced Resectable Melanoma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia